Advertisement
U.S. markets open in 2 hours 58 minutes
  • S&P Futures

    5,305.00
    -3.25 (-0.06%)
     
  • Dow Futures

    40,133.00
    -11.00 (-0.03%)
     
  • Nasdaq Futures

    18,489.00
    -14.75 (-0.08%)
     
  • Russell 2000 Futures

    2,137.00
    -1.40 (-0.07%)
     
  • Crude Oil

    81.95
    +0.60 (+0.74%)
     
  • Gold

    2,225.60
    +12.90 (+0.58%)
     
  • Silver

    24.68
    -0.07 (-0.29%)
     
  • EUR/USD

    1.0790
    -0.0040 (-0.37%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    12.96
    +0.18 (+1.41%)
     
  • GBP/USD

    1.2613
    -0.0025 (-0.20%)
     
  • USD/JPY

    151.3920
    +0.1460 (+0.10%)
     
  • Bitcoin USD

    70,340.37
    +172.16 (+0.25%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,960.03
    +28.05 (+0.35%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Exact Sciences (EXAS) Outpaces Stock Market Gains: What You Should Know

Exact Sciences (EXAS) closed the most recent trading day at $66.28, moving +1.33% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.56%. Meanwhile, the Dow gained 0.41%, and the Nasdaq, a tech-heavy index, added 1.35%.

Prior to today's trading, shares of the molecular diagnostics company had gained 6.13% over the past month. This has outpaced the Medical sector's loss of 2.2% and the S&P 500's loss of 1.48% in that time.

Investors will be hoping for strength from Exact Sciences as it approaches its next earnings release. On that day, Exact Sciences is projected to report earnings of -$0.79 per share, which would represent year-over-year growth of 24.04%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $542.46 million, up 11.49% from the year-ago period.

For the full year, our Zacks Consensus Estimates are projecting earnings of -$2.76 per share and revenue of $2.29 billion, which would represent changes of +22.03% and +9.89%, respectively, from the prior year.

Any recent changes to analyst estimates for Exact Sciences should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 1.56% higher within the past month. Exact Sciences currently has a Zacks Rank of #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 88, putting it in the top 35% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Exact Sciences Corporation (EXAS) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Advertisement